Anorexia nervosa (AN) is a mental illness with high mortality that most commonly afflicts adolescent female individuals. Clinical symptoms include chronic food refusal, weight loss and body image distortions. We carried out a genome-wide association study on 1033 AN cases and 3733 pediatric control subjects, all of whom were of European ancestry and were genotyped on the Illumina HumanHap610 platform (Illumina, San Diego, CA, USA). We confirmed that common single-nucleotide polymorphisms (SNPs) within OPRD1 (rs533123, P = 0.0015) confer risk for AN, and obtained suggestive evidence that common SNPs near HTR1D (rs7532266, P = 0.04) confer risk for restricting-type AN specifically. However, no SNPs reached genome-wide significance in our data, whereas top association signals were detected near ZNF804B, CSRP2BP, NTNG1, AKAP6 and CDH9. In parallel, we performed genome-wide analysis on copy number variations (CNVs) using the signal intensity data from the SNP arrays. We did not find evidence that AN cases have more CNVs than control subjects, nor do they have over-representation of rare or large CNVs. However, we identified several regions with rare CNVs that were only observed in AN cases, including a recurrent 13q12 deletion (1.5 Mb) disrupting SCAS in two cases, and CNVs disrupting the CNTN6/CNTN4 region in several AN cases. In conclusion, our study suggests that both common SNPs and rare CNVs may confer genetic risk to AN. These results point to intriguing genes that await further validation in independent cohorts for confirmatory roles in AN.
Introduction
Anorexia nervosa (AN) is a syndrome characterized by chronic food refusal, weight loss, irrational fear of weight gain even when emaciated, and distortions about body weight and shape. 1 Women are affected more often than men in an B10:1 ratio, with B0.9% of US women affected and a near uniform adolescent age at onset. 2 There are several subtypes of AN. 1 Those with the restricting subtype have severely diminished food intake, and those with the bingeeating/purging subtype additionally engage in bingeeating or purging behavior. Compared with other behavioral disorders, AN has a stereotypic presentation with respect to gender-specific risk, age of onset, symptoms, signs and disease course. 2 AN is associated with significant morbidity and has the highest mortality rate among all psychiatric disorders, 3 with recent estimates of a standardized mortality ratio as high as 6.2. 4 Treatment for AN is challenging as most patients lack insight into their illness and are reluctant to undergo weight restoration.
Multiple pieces of evidence suggest a strong genetic component in susceptibility to AN. A high degree of familial aggregation is observed for AN, with a firstdegree relative recurrence risk > 10. 5, 6 An increased rate of AN is also seen among first-degree relatives of bulimia nervosa probands, and vice versa. 5 Twin studies have estimated AN heritability as ranging from 58 to 74% in two studies conducted in the United States, 7 56% in a study conducted in Sweden 7 and 75% in a study conducted in Denmark. 8 The slight variability probably relates to differences in culture or ascertainment/diagnostic criteria.
Several studies have been conducted to investigate the genetic basis of AN. 9, 10 A microsatellite linkage study mapped a locus on chromosome 1, which may harbor a risk allele for the most narrow diagnostic category of AN, the restricting-type AN (RAN). 11 single-nucleotide polymorphisms (SNPs) genotyping in this region 12 boosted the linkage signal and nominated susceptibility alleles of small effect, in two plausible candidate genes, namely OPRD1 (delta opioid receptor) and HTR1D (serotonin 1D receptor). The association signals on these candidate genes were later confirmed by an independent study. 13 Linkage analyses using covariates, such as obsession-scale scores, identified multiple other genomic regions, which might harbor AN susceptibility alleles. 14, 15 Several association studies on AN using candidate genes in selected pathways have also been conducted. In addition to studies on HTR1D and OPRD1, a study tested an SNP in the serotonin 2A receptor gene, but failed to find association. 16 A few other studies have tested genes in the dopamine pathway, and detected evidence for association for DRD2 (dopamine D2), 17 but not for COMT (catechol-O-methyltransferase). 18 Positive evidence of association was also reported for BDNF (brain-derived neurotrophic factor), 19, 20 but many other candidate gene association studies have generally failed to find significant association. 21 More recently, a Japanese group conducted genome-wide investigation of AN by typing pooled DNA on microsatellite markers with follow-up SNP genotyping, and detected significant association on rs2048332 near SPATA17 on 1q41. 22 In summary, despite many linkage studies, candidate gene association studies and small-scale genome-wide association studies, the genetic architecture underlying AN susceptibility remains largely unknown.
To identify AN susceptibility loci, we performed a genome-wide association study (GWAS) using high-density SNP arrays on a large AN cohort. Given the known contribution of copy number variations (CNVs) to neuropsychiatric disorders, 23 we also performed a parallel study on CNVs, by taking advantage of the signal intensity data from SNP genotyping arrays. Here, we report the results from the analysis on both common SNPs and rare CNVs. Our study confirmed the potential role of known susceptibility genes, but also pointed to a few additional susceptibility genes and variants worthy of follow-up studies.
Materials and methods

Sample collection
The AN cases examined in this study were collected from several sources. A collaborative group to study AN genetics was formed B15 years ago, including multiple AN clinical phenotypic experts. 24 Methods, ascertainment sites and diagnostic instruments for this effort have been previously described. 24 All cases met a lifetime diagnosis of DSM-IV AN, with or without amenorrhea, at least 3 years before study entry and by age 45. The amenorrhea criterion was waived because of its unreliability in retrospective assessment in females; data suggest that anorectic women with and without amenorrhea do not differ significantly. 25 The threshold for low weight was defined as a body mass index at or below 18 kg m -2 , which corresponds to the fifth percentile body mass index values of the National Health and Nutrition Examination Survey epidemiological sample of females 26 for the average age range (27-29 years) of the probands. Eating disorder symptoms and course of illness were assessed with the structured interview for anorexic and bulimic disorders. 27 Psychiatric comorbid disorders were assessed with semi-structured interviews and diagnoses were by DSM-IV criteria, using consensus best-estimate diagnostic procedures. Attitudes toward eating were quantified with the eating disorders inventory-2, 28 whereas measures of the severity of obsessions and compulsions were quantified with the Yale-Brown Obsessive-Compulsive Scale. 29 Personality constructs were measured by the temperament and character inventory, 30 whereas perfectionism was assessed by the Multi-dimensional Perfectionism Scale. 31 Potential probands were excluded if they had a history of severe CNS trauma, psychotic disorder or developmental disability, or if they had a medical or neurological condition that could confound the diagnosis of AN (such as type 1 diabetes). In total, we genotyped 1105 unrelated AN cases in this study, with the majority being female subjects. With stringent quality control measures (see below), a total of 1033 AN cases (1009 female subjects and 24 male subjects) were left in the GWAS analysis, including 39 without subtype classification. The distribution of the age of cases was 26.9 ± 8.6 years (mean ± s.d.), whereas the age at first symptom was 15.1±3.1 years. The distribution of the lowest body mass index measure was 14.1 ± 2.0 kg m -2 , and the Yale-Brown Obsessive-Compulsive Scale was 15.1±12.4.The disease subtypes were described in Supplementary Table 1 .
The pediatric control group was recruited by the Children's Hospital of Philadelphia (CHOP) clinicians, nursing and medical assistant staff within the CHOP Health Care Network, which includes multiple primary care clinics and outpatient practices. The control subjects have linked electronic medical records in the clinical databases, and a coded version of these records can be accessed by researchers for genetic research purposes. At the time of the data analysis, the average age of the control subjects was 12.75 years with a s.d. of 4.2 years. One concern on using pediatric controls is the potential loss of power that is associated with the inability to exclude latent diagnoses of the phenotype of interest through intensive screening of controls; however, such loss of power is minimal when disease prevalence is below 1%, 32 so our study is unlikely to be significantly affected by this design. We utilized multidimensional scaling (MDS) on both AN cases and control subjects, together with 11 HapMap3 popula-tions, to ensure good matching of genetic backgrounds (Supplementary Figure 1) . Only the subsets of control subjects with genetically inferred European ancestry were used in the subsequent association analysis (Supplementary Figure 2) . All these control subjects were genotyped using the same Illumina Human610 SNP arrays (Illumina, San Diego, CA, USA) at the same genotyping facility by the same technical staff as the case subjects. To further address the concern of population stratification, we also performed association analysis by logistic regression using principal components as covariates, based on the MDS analysis of cases and control subjects of European ancestry. The results were still similar without loci reaching genome-wide significance, and the genomic control inflation factor remained at 1.08. These control subjects genotyped on Human610 arrays were not used in previous publications. The Research Ethics Board of CHOP and other participating centers approved the study, and written informed consent was obtained from all subjects or their parents.
SNP genotyping and quality control All DNA samples were genotyped on the Illumina Human610-Quad version 1 SNP arrays with B610 000 markers (including B20 000 non-polymorphic markers), at the Center for Applied Genomics, CHOP. Standard data normalization procedures and canonical genotype clustering files provided by Illumina were used to process the genotyping signals.
Following genotyping, we removed samples with > 5% missing genotypes, after excluding B20 000 nonpolymorphic markers as they do not have genotypes. We used the PLINK software version 1.06 33 for MDS on markers not in linkage disequilibrium (LD) to identify the ancestry origin (via the --mds-plot argument), and removed samples who were not of genetically inferred European ancestry. Furthermore, based on the wholegenome identity-by-descent estimate, we eliminated samples from pairs of samples showing cryptic relatedness (identity-by-descent score > 0.2). A total of 1033 AN cases and 3733 control subjects were used in subsequent association tests on SNPs.
Association tests
For the genome-wide association analysis for SNPs, we utilized the PLINK software 33 version 1.06, through Cochran-Armitage trend test. For chromosome X markers, the analysis was performed on female subjects only. Additionally, we explored association analysis on the subset of female subjects only. Furthermore, given the previous reports on the linkage signals specifically for the cases with RAN, 11 we also examined association signals by performing the analysis on the subsets of RAN cases and control subjects. Additionally, we also explored restricting the analysis on AN cases with known family history, or AN cases with an age of onset before or equal to 16 years. We set a genome-wide significance threshold as P < 1 Â 10
À8
, considering the multiple types of association tests that have been examined.
CNV calling and analysis
The Log R ratio (LRR) and B allele frequency (BAF) measures for all markers for all samples were directly calculated and exported from the Illumina BeadStudio software. The CNV calls were generated using the PennCNV software (version 2009 Aug27), 34 which utilizes an integrated hidden Markov model that incorporates multiple sources of information, including total signal intensity and allelic intensity ratio at each SNP marker, the distance between neighboring SNPs, the allele frequency of SNPs and the pedigree information where available. The default program parameters, library files and the genomic wave adjustment routine 35 in detect_cnv.pl program were used in generating CNV calls. The scan_region.pl program in PennCNV was used to map called CNVs to specific genes and exons, using the RefSeq gene definitions. The genomic coordinates for the CNV calls were generated using the NCBI build 36 human genome assembly.
Several procedures were used for quality control on the CNV calls. We first excluded all samples with LRR_standard deviation (SD) measure > 0.3, or with BAF_drift measure > 0.01, or with number of CNV calls > 75. Next, we excluded sparse CNV calls, that is, those CNV calls with average inter-marker distance > 50 kb (the average distance is B5 kb across the whole genome for the arrays that we used). Furthermore, we excluded all CNV calls whose > 50% genomic span overlap with known immunoglobulin regions (chr22: 20715572-21595082, chr14:105065301-106352275, chr2: 88937989-89411302, chr14:21159897-22090937), as these CNVs may be a result of somatic changes. In addition, we excluded CNV calls whose > 50% genomic span overlap with centromere (a list of genomic coordinates for centromere in human genome NCBI 36 build were given at the PennCNV website FAQ section). The final set of CNV calls were then used in the comparative analysis between AN cases and control subjects. Large CNV calls that were potentially interesting were each visually confirmed using a custom script in PennCNV that generates JPG image files for CNVs.
Results
Genome-wide association of SNP data
We performed a GWAS in 1033 AN cases and 3773 pediatric control subjects, all of whom were genotyped by the Illumina Human610 SNP array with over 598 000 SNP markers. We utilized MDS analysis on a subset of SNP markers not in LD, to ensure that only samples with genetically inferred European ancestry were used in association tests (Supplementary Figure 1) and to ensure that cases and control subjects were well matched in their genetic ancestry (Supplementary Figure 2 ). The Manhattan plot for the wholegenome association tests was given in Figure 1 .
None of the SNPs reached a stringent level of genome-wide significance, and the most significant marker is rs6959888 within ZNF804B on 7q21, with a P-value of 1.6 Â 10 À6 (Table 1) . Its paralog ZNF804A
was previously associated with schizophrenia, 36 but the function for neither gene has been characterized. The list of 10 additional most associated loci with P < 1 Â 10 À6 were annotated in Table 1 . Of note, several loci, including APAK6, SSBP2, FAM155A, LPP2 and ELAVL2, harbor multiple SNPs with nominal significance levels. Performing logistic regression-based association tests incorporating principal components as covariates had minor effects on the results (Supplementary Table 2 Table 6 ) and (4) 489 cases with age of diagnosis p16 years and 3773 control subjects (Supplementary Table 7 ). Considering the several types of association tests that we have performed, appropriate genome-wide significance threshold should be regarded as P < 1 Â 10
À8
. When examining female subjects only, most of the SNPs showed decreased significance, except an SNP located within the intergenic region between CDH10 and CDH9 (P = 2.5 Â 10
). The region was previously associated with autism spectrum disorders, 37 but the autismassociated SNP rs4307059 does not show evidence of association with AN (P = 0.45). When comparing subjects with RAN and control subjects, none of the loci showed stronger evidence of association. When comparing cases with family history and control subjects, none of the loci showed stronger evidence of association. Similarly, when comparing subjects with early onset diagnosis and control subjects, we do not observe stronger evidence of association either. In summary, the list of loci in Table 1 did not reveal obvious candidate genes, but they represented a prioritized list of genes worthy of follow-up studies in additional independent cohorts.
Examination of previously reported candidate variants
We next examined whether we can confirm specific variants that were associated with AN in previously Figure 1 The Manhattan plot of logarithm of P-values vs genomic coordinates for whole-genome single-nucleotide polymorphism (SNP) markers. GWAS, genome-wide association study. published studies. Two independent studies have shown that two variants located in OPRD1 and HTR1D on the 1p33-36 linkage region were associated with AN. 12, 13 In the recent Brown et al. 13 study, rs569356 within OPRD1 showed association with AN and RAN, whereas rs856510 and rs674386 (r 2 = 1 with each other) within HTR1D showed weak evidence of association with RAN only. In our study, we examined the SNP rs533123 within OPRD1 (r 2 = 0.95 with rs569356 and 4 kb away), and confirmed its association and direction of effects with AN (P = 1.5 Â 10
À3
, odds ratio = 1.2, minor allele frequency (MAF) = 21.7% in cases, MAF = 18.6% in controls). We also examined rs7532266 near HTR1D (r 2 = 1 with rs674386 and 30 kb away), but did not find evidence of association (P = 0.44, MAF = 31.1% in cases, MAF = 32.0% in controls). As the Brown et al. study showed association between HTR1D and RAN, but not with the broader diagnosis of AN, we also compared the subset of RAN cases and control subjects. We detected weak association signals for rs7532266 (P = 0.04, MAF = 28.5% in RAN cases) with the allelic effects observed in the same direction as previous reports. 13 There is no sample overlap between the Brown et al. and our study, and combining these studies by Fisher's combined method showed that OPRD1 is associated with AN (P = 1.76 Â 10
À5
), yet HTR1D is specifically associated with RAN (P = 0.006).
We also examined the SNP rs2048332 on 1q41 reported in a Japanese study. 22 This SNP was not placed on the Illumina Human610 array, so we examined rs6604568 instead, which has r 2 = 0.84 with rs2048332 and is only 15.6 kb away. The SNP rs6604568 was not associated with AN in our study (P = 0.13, MAF = 28.0% in cases, MAF = 29.7% in controls). Comparing RAN cases and control subjects did not reveal any association either (P = 0.62), suggesting that the previously reported association signals may be ethnicity specific. Furthermore, a CAG repeat polymorphism in KCNN3 has been associated with AN. 38, 39 The CAG repeat was not annotated in HapMap samples, so we examined all SNPs within KCNN3. We identified 85 SNPs within KCNN3 and 6 SNPs near KCNN3 (0.3-27 kb away), with the most significant SNP being rs906281 (P = 0.002). However, the SNPs may not tag the CAG repeat polymorphism.
Genome-wide investigation of CNVs
Besides common SNPs, rare CNVs have been associated with multiple related neuropsychiatric disorders, including schizophrenia, 40 ,41 autism 42 and bipolar disorder. 43 Thus, we next examined the role of rare CNVs in predisposing to AN. Using signal intensity data from SNP arrays, we generated CNV calls for 1015 AN cases and 3532 control subjects who passed quality control measures by PennCNV. 34 As increased 'CNV load' has been reported in schizophrenia cases, 40 we first examined whether we can find more CNVs in AN cases than control subjects. We caution that these types of 'load' analysis may be highly susceptible to data biases caused by signal quality in genotyping experiments, so we investigated several different thresholds for CNV calling. When utilizing default PennCNV parameters for CNV calling (X3 markers), we observed slightly fewer CNVs in cases than controls (30.4 vs 31.2 per subject). When restricting the analysis to a set of more confident CNV calls (X10 markers, CNVX100 kb), we observed a similar number of CNVs in cases vs control subjects (3.0 vs 3.2 per subject). When examining large CNVs (X10 markers, CNVX1 Mb), similar observations were made (0.12 vs 0.12 per subject). No CNVs in cases or control subjects were > 2 Mb.
Given the similarity of total CNV loads in AN cases and control subjects, we next assessed whether AN cases tend to have more rare CNVs. For this analysis, we defined common CNV regions as those regions disrupted in > 1% subjects, and then classified CNVs as 'common' if > 50% of their genomic span overlap with a common CNV region, or 'rare' otherwise. In AN cases and control subjects, 22.7 and 22.7% of the CNVs were classified as rare CNVs, respectively. When examining rare CNVs > 100 kb, > 500 kb or > 1 Mb, we still could not obtain evidence that rare CNVs were over-represented in AN cases compared with control subjects. Therefore, the 'genetic load' of rare CNVs may have a less important function in AN susceptibility than in other psychiatric disorders.
Rare CNVs in AN cases point to specific regions and genes As no CNV studies on AN have been published, we do not have any specific CNV findings to confirm. Instead, we first focused on a few CNVs implicated in other neuropsychiatric diseases such as schizophrenia, autism and epilepsy. 40, [44] [45] [46] [47] [48] These include recurrent deletions/duplications on 1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.1 and 22q11.2 as well as > 100 kb exonic deletions on NRXN1, all of which are very large and can be readily detected by the current SNP arrays. Given the small sample size, we did not expect to detect an association, and, therefore, presented descriptive results. In AN cases, we detected one 1.5 Mb deletion and one duplication on 1q21.1, three 370 kb deletions and 13 duplications on 15q11.2, one 800 kb deletion and one duplication on 16p13.1, as well as one 530 kb duplication on 16p11.2. These individuals are all female. Clinically, they do not appear to stand out relative to other cases with the exception that the case with the 1q21.1 deletion reported a lifetime minimum body mass index of 11.4, which is extremely low, even for individuals with AN. In comparison, in control subjects, we observed 16 deletions and 21 duplications on 15q11.2, one deletion on 15q13.3, two deletions and eight duplications on 16p13.1, one deletion and three duplications on 16p11.2. Although the 15q11.2 duplication showed some evidence of association (P = 0.036, two-sided Fisher's exact test), it did not pass adjustment for multiple testing. These Abbreviations: AN, anorexia nervosa; CNV, copy number variation; Del, deletions; Dup, duplications; SNP, single-nucleotide polymorphism.
A GWAS on common SNPs and rare CNVs in AN K Wang et al results were also summarized in Supplementary  Table 8 . We next examined rare and large CNVs in AN cases to determine whether some of them tended to cluster in the same genomic region (Table 2) . Interestingly, we identified a large and rare CNV on 13q12 (chr13:22426685-23795901, B1.4 Mb) that was present in two AN cases (Figure 2a) . The CNVs were not detected in control subjects in our study. To identify the true population frequency of this particular CNV, we subsequently examined a larger data set comprising over 72 918 subjects genotyped by the Illumina Figure 2 Genome Browser shots and visual validation on (a) 13q12 deletions and (b) deletions/duplications disrupting the CNTN4/CNTN6 region. The predicted copy number variation (CNV) region was enclosed within two gray vertical lines, whereas the red dots represent markers within the CNV. The Log R ratio (LRR) plot shows total signal intensity, and decreased or increased LRR suggests the presence of deletions or duplications. The B allele frequency (BAF) plot shows allelic intensity ratio, and lack of BAF around 0.5 suggests the presence of deletions, yet BAF clusters around 0.33 and 0.66 suggest the presence of duplications.
550K or 610K arrays (all samples were genotyped at the CHOP), and identified 38 subjects carrying the 13q12 CNV ( > 80% base overlap), including 15 deletions and 23 duplications. Therefore, the population frequency of this deletion is B1/5000 vs 1/500 for AN; however, this 10-fold enrichment could be inflated by winner's curse, and we note that the 95% confidence interval for odds ratio is 1.06-41.3. Several genes were enclosed in this CNV; among them, SCAS is highly expressed in neuronal tissues, and mutations in this gene result in autosomal recessive spastic ataxia. 49 Additionally, one duplication (877 kb) and one deletion (952 kb) both disrupt the CNTN6 and CNTN4 genes and their intergenic regions (Figure 2b ). Deletions or translocations at this region have been reported in autism, developmental delay and other diseases. 50, 51 Considering that the case:control ratio in our data set is not 1:1, in addition to the analysis on case-specific CNVs, we also listed all large and rare ( > 500 kb, < 1%) CNVs in Table 2 . Given the relatively small sample size, none of these regions would reach statistical significance. However, rare genetic variations with high penetrance may point to important candidate genes that are worthy of follow-up analysis.
Discussion
In this study, we performed genome-wide investigation of both SNPs and CNVs to identify genetic variants associated with AN. To our knowledge, this is the first study that utilized whole-genome and high-density genotyping technology to investigate the genetic basis of AN, and our analysis identified specific genes and regions that are worthy of additional studies in independent cohorts. However, while the CNV loci identified are compelling, we also wish to discuss several caveats related to the study design and the interpretation of the results.
First, despite the relatively large sample size ( > 1000 cases) compared with any previous association studies on AN, we were still unable to find genome-wide significant signals. This observation is similar to previous modest-size studies on bipolar disorder and schizophrenia, and may suggest that much larger sample sizes are needed to identify common variants with small effects for neuropsychiatric disorders. Alternatively, it may also suggest that rare variants probably have more significant functions for AN, and are hence difficult to detect without much larger sample sizes in GWAS. This observation motivates us to supplement common SNP analysis with rare CNV analysis. However, we were unable to garner support that rare CNVs tend to be enriched in cases compared with control subjects. While acknowledging that such 'genetic load' analysis is highly susceptible to noises in the data and differential biases in genotyping experiments, these results seem to suggest that rare variants, including recurrent CNVs and non-recurrent ones, appear to have a less important function, compared with other psychiatric illness such as schizophrenia and autism. 40, 41, 44, 45 Second, compared with SNPs, given the rare nature of large CNVs that disrupt genes, it requires even larger sample sizes to establish the true association of CNVs and disease phenotypes. Therefore, although the genes identified by our rare CNV analysis (Table 2) are intriguing candidates, additional sample sets with whole-genome genotyping data are necessary to further validate these results and establish confirmatory associations. On the other hand, in this study, we did not specifically test for common CNVs, in part because common CNVs tend to be small (with increased false negative rates to detect by computer algorithms), and they are already well tagged by the SNP genotyping arrays. 52 Finally, given that the phenotypic presentation of AN could differ between various subtypes, we have also performed subgroup-based analysis on multiple subgroups, including RAN, AN cases with family history, or AN cases with early age of diagnosis. However, none of these subtype analysis yielded genome-wide significant results. We note that this analysis further reduced sample size, so it has even smaller power to detect true associations. Nevertheless, it would be important and reasonable to explore whether specific association signals tend to be stronger or even tend to exist exclusively in specific subtypes of the diseases. For example, in our study, the OPRD1 association with AN was observed exclusively in the comparison between RAN and control subjects, and no evidence of association was found for the entire AN group.
We also find it important to discuss our results in comparison with other neuropsychiatric/neurodevelopmental diseases such as schizophrenia, bipolar disorder and autism spectrum disorders. Unlike other psychiatric disorders, the clinical diagnosis of AN is relatively straightforward, and it is much less likely that an incorrect diagnosis is given to AN cases. Additionally, the phenotypes are much less heterogeneous than affective disorders or autism spectrum disorders. Therefore, one would assume that phenotypic heterogeneity is less of a concern for AN. On the other hand, there are several unique challenges for the genetic analysis of AN. Compared with other psychiatric disorders, AN may be more likely to be related to cultural differences, which may complicate the genetic studies. The relative contributions of culture and biology to AN have been long debated in this field; future association analyses that incorporate cultural background or socioeconomic status may lead to improved power and precision to identify AN genes.
In conclusion, through genome-wide association analysis of both SNPs and CNVs, we have confirmed two previously published candidate genes, yet also identified additional genes that are likely to be involved in AN pathogenesis. These genes require testing in additional independent data sets. The study illustrates the importance of using whole-genome and unbiased genomic survey to identify disease susceptibility genes and mechanisms.
